Evolution of tigecycline- and colistin-resistant CRKP (carbapenem-resistant Klebsiella pneumoniae) in vivo and its persistence in the GI tract

Emerg Microbes Infect. 2018 Jul 9;7(1):127. doi: 10.1038/s41426-018-0129-7.

Abstract

Emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) strains that also exhibit resistance to tigecycline and colistin have become a major clinical concern, as these two agents are the last-resort antibiotics used for treatment of CRKP infections. A leukemia patient infected with CRKP was subjected to follow-up analysis of variation in phenotypic and genotypic characteristics of CRKP strains isolated from various specimens at different stages of treatment over a period of 3 years. Our data showed that (1) carbapenem treatment led to the emergence of CRKP in the gastrointestinal (GI) tract of the patient, which subsequently caused infections at other body sites as well as septicemia; (2) treatment with tigecycline led to the emergence of tigecycline-resistant CRKP, possibly through induction of the expression of a variant tet(A) gene located in a conjugative plasmid; (3) colistin treatment was effective in clearing CRKP from the bloodstream but led to the emergence of mcr-1-positive Enterobacteriaceae strains as well as colistin-resistant CRKP in the GI tract due to inactivation of the mgrB gene; and (4) tigecycline- and colistin-resistant CRKP could persist in the human GI tract for a prolonged period even without antibiotic selection pressure. In conclusion, clinical CRKP strains carrying a conjugative plasmid that harbors the blaKPC-2 and tet(A) variant genes readily evolve into tigecycline- and colistin-resistant CRKP upon treatment with these two antibiotics and persist in the human GI tract.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antifungal Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use
  • Caspofungin
  • Colistin / pharmacology
  • Colistin / therapeutic use
  • Diarrhea / microbiology*
  • Diarrhea / physiopathology
  • Drug Resistance, Bacterial / drug effects*
  • Echinocandins / therapeutic use
  • Feces / microbiology*
  • Gastrointestinal Tract / microbiology*
  • Humans
  • Klebsiella Infections / drug therapy
  • Klebsiella Infections / microbiology*
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / isolation & purification
  • Leukemia, Monocytic, Acute / drug therapy*
  • Leukemia, Monocytic, Acute / physiopathology
  • Lipopeptides / therapeutic use
  • Male
  • Microbial Sensitivity Tests
  • Minocycline / analogs & derivatives
  • Minocycline / therapeutic use
  • Tigecycline
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Carbapenems
  • Echinocandins
  • Lipopeptides
  • Tigecycline
  • Caspofungin
  • Minocycline
  • Colistin